PRODUCT INFORMATION



Sarpogrelate-d₃ (hydrochloride)

Item No. 33472

CAS Registry No.: 2934185-00-7

Formal Name: butanedioic acid, 1-[2-(dimethylamino)-1-

> [[2-[2-[3-(methoxy-d₂)phenyl]ethyl]phenoxy] methyl]ethyl] ester, monohydrochloride

C₂₄H₂₈D₃NO₆ • HCl

FW: 469.0

Chemical Purity: ≥98% (Sarpogrelate (hydrochloride))


Deuterium

MF:

Incorporation: \geq 99% deuterated forms (d₁-d₂); \leq 1% d₀

Supplied as: A solid -20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Sarpogrelate-d2 (hydrochloride) is intended for use as an internal standard for the quantification of sarpogrelate (hydrochloride) (Item No. 24194) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Sarpogrelate-d₃ (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the sarpogrelate-d3 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Sarpogrelate-d₃ (hydrochloride) is soluble in organic solvents such as methanol and DMSO.

Description

Sarpogrelate is a selective antagonist of the serotonin (5-HT) receptor subtypes 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} (K_i s = 3.02, 269, and 37.2 nM, respectively, for human recombinant receptors expressed in CHO-K1 cells). It is selective for 5-HT₂ (K_i = 70.8 nM) over 5-HT₁ (K_i = >26,000 nM), α_1 -, α_2 -, and β -adrenergic $(K_i s = 640-123,800 \text{ nM})$, and muscarinic receptors $(K_i = >40,000 \text{ nM})$. In vitro, it inhibits aggregation of rat whole blood induced by collagen, 5-HT (Item No. 14332) with collagen, and 5-HT with ADP (Item No. 16778; IC₅₀s = 57.7, 0.56, and 22.7 μM, respectively).³ In vivo, it inhibits leukocyte-endothelial interactions in the femoral artery induced by a high-fat high-fructose diet (HFFD) in mice when administered at a dose of 5 mg/kg per day. ⁴ Sarpogrelate (5 mg/kg per day) decreases ventricular hypertrophy and infarct size in a rat model of myocardial infarction.⁵

References

- 1. Rashid, M., Manivet, P., Nishio, H., et al. Life Sci. 73(2), 193-207 (2003).
- 2. Maruyama, K., Kinami, J., Sugita, Y., et al. J. Pharmacobiodyn. 14(4), 177-181 (1991).
- 3. Kubacka, M., Kazek, G., Kotańska, M., et al. Eur. J. Pharmacol. 818, 263-270 (2018).
- 4. Kataoka, H., Ariyama, Y., Deushi, M., et al. PLoS One 11(1), e0147929 (2016).
- 5. Brasil, D., Temsah, R.M., Kumar, K., et al. J. Cardiovasc. Pharmacol. Ther. 7(1), 53-59 (2002).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 09/06/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM